
Citius Pharmaceuticals CTXR
$ 0.51
4.08%
Citius Pharmaceuticals Total Shareholders Equity | CTXR
Annual Total Shareholders Equity Citius Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 67.6 M | 70.1 M | 90.8 M | 103 M | 132 M | 33.7 M | 24.4 M | 27.9 M | 21.9 M | 16.8 M | -635 K | -742 K | -2.9 M | -1.61 M | -23.8 K | 2.5 K |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | -2.9 M | 36.4 M |
Quarterly Total Shareholders Equity Citius Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61.5 M | 80 M | 80 M | 67.6 M | 65.1 M | 60.7 M | 68.9 M | 70.1 M | 86.3 M | 80 M | 85.3 M | 90.8 M | 98.3 K | 91.8 M | 101 M | 103 M | 110 M | 118 M | 125 M | 132 M | 137 M | 126 M | 25.8 M | 33.7 M | 33.7 M | 25.2 M | 23.2 M | 27.2 M | 20.4 M | 20.4 M | 27 M | 24.2 M | 24.2 M | 24.2 M | 25.9 M | 21.9 M | 21.9 M | 25.9 M | 15.2 M | 16.8 M | 16.8 M | 16.8 M | -1.59 M | -635 K | -635 K | -635 K | -824 K | -742 K | -742 K | -742 K | -2.9 M | -14.7 K | -14.7 K | -15 K | -1.61 M | -45.8 K | -45.8 K | -47.3 K | -1.06 M | -23.8 K | -23.8 K | -26.4 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 137 M | -2.9 M | 38.7 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Concert Pharmaceuticals
CNCE
|
112 M | - | - | $ 401 M | ||
|
Histogen
HSTO
|
14.4 M | - | 31.6 % | $ 2.12 M | ||
|
Checkpoint Therapeutics
CKPT
|
-12.6 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
-279 M | - | -7.23 % | $ 13 M | ||
|
Taro Pharmaceutical Industries Ltd.
TARO
|
1.73 B | - | - | $ 1.62 B | ||
|
Omeros Corporation
OMER
|
-121 M | $ 13.23 | -5.71 % | $ 840 M | ||
|
BioLineRx Ltd.
BLRX
|
23.3 M | $ 0.94 | -10.44 % | $ 2.32 B | ||
|
PhaseBio Pharmaceuticals
PHAS
|
-93 M | - | 7.4 % | $ 6.29 M | ||
|
Forma Therapeutics Holdings
FMTX
|
498 M | - | - | $ 958 M | ||
|
Blueprint Medicines Corporation
BPMC
|
299 M | - | - | $ 8.14 B | ||
|
Horizon Therapeutics Public Limited Company
HZNP
|
5.07 B | - | - | $ 26.6 B | ||
|
Provention Bio
PRVB
|
122 M | - | - | $ 2.37 B | ||
|
Reata Pharmaceuticals
RETA
|
-65.7 M | - | - | $ 6.29 B | ||
|
PainReform Ltd.
PRFX
|
8.54 M | $ 0.47 | -24.53 % | $ 305 K | ||
|
iTeos Therapeutics
ITOS
|
590 M | - | - | $ 411 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
5.59 M | $ 1.44 | -2.03 % | $ 2.37 M | ||
|
PolarityTE
PTE
|
16.6 M | - | -0.82 % | $ 1.78 M | ||
|
Kronos Bio
KRON
|
87.6 M | - | 1.49 % | $ 50.8 M | ||
|
Cullinan Management
CGEM
|
409 M | $ 8.9 | -1.93 % | $ 536 M | ||
|
CRISPR Therapeutics AG
CRSP
|
1.92 B | $ 39.15 | 0.57 % | $ 3.52 B | ||
|
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | ||
|
Stoke Therapeutics
STOK
|
352 M | $ 26.77 | -0.59 % | $ 1.59 B | ||
|
Trevena
TRVN
|
-7.66 M | - | -46.58 % | $ 31.8 M | ||
|
Calithera Biosciences
CALA
|
20.4 M | - | -10.95 % | $ 876 K | ||
|
Molecular Templates
MTEM
|
4.21 M | - | -23.43 % | $ 495 K | ||
|
Oncorus
ONCR
|
60.5 M | - | -8.54 % | $ 3.19 M | ||
|
BioXcel Therapeutics
BTAI
|
-95.5 M | $ 0.07 | 9.81 % | $ 855 K | ||
|
Novan
NOVN
|
4.6 M | - | -24.84 % | $ 2.64 M | ||
|
CohBar
CWBR
|
15.3 M | - | -15.44 % | $ 2.2 M | ||
|
NeuBase Therapeutics
NBSE
|
18.2 M | - | -1.56 % | $ 12.3 M | ||
|
Epizyme
EPZM
|
-20.7 M | - | - | $ 249 M | ||
|
Arena Pharmaceuticals
ARNA
|
673 M | - | -6.81 % | $ 3.04 B | ||
|
Scopus BioPharma
SCPS
|
-6.56 M | - | -48.37 % | $ 3.71 M | ||
|
Nabriva Therapeutics plc
NBRV
|
3.29 M | - | - | $ 4.55 M | ||
|
Annovis Bio
ANVS
|
16.9 M | $ 0.71 | -3.81 % | $ 14.6 M | ||
|
scPharmaceuticals
SCPH
|
13.3 M | - | - | $ 218 M | ||
|
Entasis Therapeutics Holdings
ETTX
|
31.2 M | - | - | $ 105 M | ||
|
Athersys
ATHX
|
-23.9 M | - | 3.77 % | $ 22.4 M | ||
|
Global Blood Therapeutics
GBT
|
196 M | - | - | $ 4.62 B | ||
|
Inozyme Pharma
INZY
|
57.8 M | - | - | $ 207 M | ||
|
NanoString Technologies
NSTG
|
45.8 M | - | -37.43 % | $ 5.1 M | ||
|
Humanigen
HGEN
|
-46.8 M | - | -81.12 % | $ 4.28 M | ||
|
CNS Pharmaceuticals
CNSP
|
4.52 M | $ 3.56 | -9.07 % | $ 1.58 M | ||
|
Sorrento Therapeutics
SRNE
|
-18.6 M | - | -29.58 % | $ 126 M | ||
|
Surface Oncology
SURF
|
93.4 M | - | - | $ 59.7 M | ||
|
Sierra Oncology
SRRA
|
96 M | - | -0.05 % | $ 1.34 B | ||
|
Vaccinex
VCNX
|
-2.49 M | - | -61.37 % | $ 654 K | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
-6.78 M | - | -19.68 % | $ 18.4 M | ||
|
Jounce Therapeutics
JNCE
|
183 M | - | - | $ 98.4 M | ||
|
Cocrystal Pharma
COCP
|
6.33 M | $ 0.93 | -4.11 % | $ 10.5 M |